Ranibizumab versus Bevacizumab for the Treatment of Idiopathic Choroidal Neovascularization: 2-Year Results

Zhou, Pengyi; Yang, Lin; Jin, Xuemin

doi:10.5301/ejo.5000691

Cited by 10 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparative studies have shown promising outcomes of anti-VEGF therapy for ICNV, but few have demonstrated the long-term efficacy [7][8][9][10]. The aim of the present study was to investigate the prognostic factors and incidence of CNV recurrence related to retinal morphological changes of ICNV.…”

Section: Discussionmentioning

confidence: 94%

“…Currently, there are several available treatment options for ICNV, including intravitreal injection of anti-vascular endothelial growth factor (VEGF) such as ranibizumab, aflibercept and the off-label use of bevacizumab, which has previously been shown to be effective in the treatment of ICNV [7][8][9][10]. Since the majority of ICNV patients are under the age of 50 [11], it is necessary to study the longterm efficiency of this treatment.…”

Section: (Continued From Previous Page)mentioning

confidence: 99%

“…Since the majority of ICNV patients are under the age of 50 [11], it is necessary to study the longterm efficiency of this treatment. The follow-up period in previous studies has been relatively short, usually within 2 years [7,8,10]. Therefore, longer follow-up periods were needed for ICNV patients to investigate the prognosis as well as the possibility of disease recurrence.…”

Section: (Continued From Previous Page)mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Feng

Liu

et al. 2020

BMC Ophthalmol

View full text Add to dashboard Cite

Background: This study aimed to evaluate the visual and morphological outcomes of intravitreal anti-VEGF therapy and the recurrence for idiopathic choroidal neovascularization (ICNV). Methods: This retrospective study included 35 patients (35 eyes) with ICNV from July 2012 to October 2017. All patients received 1 intravitreal anti-VEGF injection followed by pro re nata injections until there was no sign of ICNV activity. This was defined as the first follow-up period. To evaluate ICNV recurrence, we continued to follow-up 27 of the 35 patients for at least 2 years after the initial diagnosis, and the longest follow-up period was 5 years. Additional injection was performed when ICNV recurred. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded and morphological improvement in optical coherence tomography (OCT) was assessed. Parameters that affect prognosis and recurrence were analysed.Results: The mean follow-up period was 168.0 ± 34.82 weeks. Mean BCVA improved from 56.20 ± 14.13 letters at baseline to 73.31 ± 12.57 letters (P<0.01); Mean CRT decreased from 353.6 ± 98.70 μm at baseline to 273.1 ± 53.56 μm (P < 0.001) at the end of the first follow-up period. Better baseline BCVA indicated a better morphological improvement (P = 0.026) in OCT: the lesion had completely subsided with recovery of the foveal contour. Those with high baseline BCVA (more than 60 letters) showed significant resolution of CNV lesions (P = 0.036). ICNV recurred in six patients (22.2%), 1 of whom experienced 2 recurrences. The mean timing of recurrence was 90.83 ± 49.02 weeks after diagnosis. There was no significant correlation between ICNV recurrence and the morphological improvement (P = 0.633). The final BCVA in patients with recurrence did not differ from that in patients without recurrence (P = 0.065).

show abstract

Section: Discussionmentioning

confidence: 94%

Section: (Continued From Previous Page)mentioning

confidence: 99%

Section: (Continued From Previous Page)mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Feng

Liu

et al. 2020

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Since the majority of ICNV patients are under the age of 50 (11), it is necessary to study the long-term efficiency of this treatment. The follow-up period in previous studies has been relatively short, usually within 2 years (7,8,10). Therefore, longer follow-up periods were needed for ICNV patients to investigate the prognosis as well as the possibility of disease recurrence.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Feng

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background This study aimed to evaluate the visual and morphological outcomes of intravitreal anti-VEGF therapy and the recurrence for idiopathic choroidal neovascularization (ICNV). Methods This retrospective study included 35 patients (35 eyes) with ICNV from July 2012 to October 2017. All patients received 1 intravitreal anti-VEGF injection followed by pro re nata injections until there was no sign of ICNV activity. This was defined as the first follow-up period. To evaluate ICNV recurrence, we continued to follow-up 27 of the 35 patients for at least 2 years after the initial diagnosis, and the longest follow-up period was 5 years. Additional injection was performed when ICNV recurred. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded and morphological improvement in optical coherence tomography (OCT) was assessed. Parameters that affect prognosis and recurrence were analysed. Results The mean follow-up period was 168.0 ± 34.82 weeks. Mean BCVA improved from 56.20 ± 14.13 letters at baseline to 73.31 ± 12.57 letters (P＜0.01); Mean CRT decreased from 353.6 ± 98.70 μm at baseline to 273.1 ± 53.56 μm (P < 0.001) at the end of the first follow-up period. Better baseline BCVA indicated a better morphological improvement(P = 0.026) in OCT: the lesion had completely subsided with recovery of the foveal contour. Those with high baseline BCVA (more than 60 letters) showed significant resolution of CNV lesions (P = 0.036). ICNV recurred in six patients (22.2%), 1 of whom experienced 2 recurrences. The mean timing of recurrence was 90.83± 49.02 weeks after diagnosis. There was no significant correlation between ICNV recurrence and the morphological improvement (P = 0.633). The final BCVA in patients with recurrence did not differ from that in patients without recurrence (P=0.065). Conclusions Intravitreal anti-VEGF therapy on a pro re nata basis was effective for treating ICNV. High baseline BCVA indicated a better prognosis. Re-treatment with anti-VEGF could effectively lead to resolution of recurrent ICNV. Disease recurrence had no significant effect on final visual prognosis and had no correlation with the morphological improvement during treatment, suggesting that follow-up for subsequent monitoring should be performed in all ICNV patients.

show abstract

Idiopathic Choroidal Neovascularization

Almarek

Alsulaiman

2020

Choroidal Neovascularization

View full text Add to dashboard Cite

Ranibizumab versus Bevacizumab for the Treatment of Idiopathic Choroidal Neovascularization: 2-Year Results

Abstract: Bevacizumab and ranibizumab are effective and safe in the treatment of ICNV, with similar effects in improving visual acuity and reducing retinal edema. The long-term efficacy of ranibizumab is superior to bevacizumab in reducing CRT.

Cited by 10 publications

References 18 publications

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization

Idiopathic Choroidal Neovascularization

Contact Info

Product

Resources

About